Stipend and Dates

Up to $15,800.

All dates and times are tenative and may change. You cannot pick which cohort you go into. The first cohort is filled before patients are placed in the next one. Cohort 6B
Day -1 Admit Mar 23, 2023
Day 3 Discharge Mar 26
Day 5 Outpatient visit Mar 28
Day 8 Admit Mar 31
Day 10 Discharge Apr 02
Day 15 Admit Apr 07
Day 17 Discharge Apr 09
Day 22 Admit Apr 14
Day 24 Discharge Apr 16
Day 29 Admit Apr 21
Day 31 Discharge Apr 23
Day 36 Admit Apr 28
Day 38 Discharge Apr 30
Day 40 Outpatient visit May 02
Day 43 Outpatient visit May 05
Day 50 Outpatient visit May 12
Day 64 Outpatient visit May 26
Day 85 Outpatient visit Jun 16
Day 92 Outpatient visit Jun 23


Click here to make an appointment for AL 0180-0032 MAD

Or call 210-225-5437 for more information


Study Criteria

Healthy Males and Females (Child bearing and non-child bearing allowed)

Age:  18-65

BMI:  18.5-29.9 – Must weigh at least 110 pounds


Study Information

Indication: The investigational drug is being developed as a possible treatment for a chronic skin condition.                                                                                                                                                                                                                                                                                                                                                                                                                                                       

Route of Administration: Subcutaneous

Washout from previous study: Participation in a clinical study and received treatment within 30 days prior to Day -1.

A woman is considered to be of childbearing potential unless she has been surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy or has been post-menopausal for at least 2 years and a man is considered to be potent unless he has been surgically sterilized (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate.

Males with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception during the study.  Male subjects must continue to use contraception (condoms plus a second effective method) for 165 days following administration of the study drug. Male subjects must agree not to donate sperm during the study and for 165 days following administration of the study drug.

Women of childbearing (WOCBP) must have a negative serum pregnancy test result within 7 days prior to the first dosing plus a negative pregnancy test pre-dose prior to dosing and must be willing to use a highly effective form of contraception for the duration of the study and for at least 3 months after the last dose of study medication. Methods like periodic abstinence, post-ovulation procedures and withdrawal are not considered adequate.


Study Reminders

  • 4 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment (including prescription, over the counter, herbal supplements and vitamins)
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a valid government issued identification card such as a driver's license, state issued ID card or passport.  You will be required to show this same photo ID at all study visits
  • Arrive 30 minutes before your appointment to complete paper work.
AL 0180-0032 MAD
Healthy Adults
If you dosed or disqualified for the SAD part of this study, you CANNOT screen. NOT CURRENTLY SCREENING.
Male or Female
Payment amount
Up to $15,800
18 - 65